March 20, 2019 08:14 AM EDT

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

John Carroll

Editor & Founder

The venture group that has launched a fleet of new biotechs in recent years, piecing together billions in syndicate cash, has $824 million more to build its next generation of life sciences companies.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Flag­ship ties up a mon­ster $824M fund to back a new wave of biotech star­tups seed­ed in their lab

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva